SETH LERNER to Carcinoma, Renal Cell
This is a "connection" page, showing publications SETH LERNER has written about Carcinoma, Renal Cell.
Connection Strength
1.207
-
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. J Clin Oncol. 2024 Nov 20; 42(33):3911-3916.
Score: 0.198
-
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2024 08 01; 7(8):e2425288.
Score: 0.196
-
Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU Int. 2024 10; 134(4):596-601.
Score: 0.196
-
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial. Eur Urol. 2024 Sep; 86(3):258-264.
Score: 0.194
-
Renal cell carcinoma with an infrarenal vena caval tumor thrombus. Urology. 1999 Sep; 54(3):561.
Score: 0.140
-
Renal cell carcinoma and situs inversus viscerum. J Urol. 1998 Dec; 160(6 Pt 1):2141-2.
Score: 0.132
-
Renal cell carcinoma extending into the retrohepatic inferior vena cava. Tex Heart Inst J. 2014 Dec; 41(6):671-2.
Score: 0.100
-
Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol. 2005 Apr; 29(4):443-51.
Score: 0.051